Class Action Announcement for Ultragenyx Pharmaceutical Inc. (RARE): Kessler Topaz Meltzer & Check, LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against Ultragenyx Pharmaceutical Inc.

Core Viewpoint - A securities fraud class action lawsuit has been filed against Ultragenyx Pharmaceutical Inc. for allegedly making false and misleading statements regarding its drug setrusumab during the class period from August 3, 2023, to December 26, 2025 [2][5]. Summary by Relevant Sections Lawsuit Details - The lawsuit is filed in the United States District Court for the Northern District of California, under the case name Bailey v. Ultragenyx Pharmaceutical Inc., et al, Case No. 3:26-cv-01097 [2]. - Investors have until April 6, 2026, to file for lead plaintiff status [2][5]. Allegations - The complaint alleges that Ultragenyx misrepresented its knowledge about the effects of setrusumab on patients with Osteogenesis Imperfecta and downplayed the risks associated with the Phase III Orbit study [3]. - It is claimed that Ultragenyx's optimism regarding the study results was unfounded, as the Phase II results lacked a placebo control group, raising concerns about the validity of the reported reduction in annualized fracture rate (AFR) [3]. - The lawsuit asserts that the positive statements made by the company regarding its business and prospects were materially misleading [3]. Investor Actions - Investors affected by the alleged fraud are encouraged to contact Kessler Topaz Meltzer & Check, LLP for recovery options at no cost [5][6]. - The lead plaintiff process allows investors to seek representation in the lawsuit, with the deadline set for April 6, 2026 [4][6]. Law Firm Information - Kessler Topaz Meltzer & Check, LLP is a prominent law firm specializing in securities-fraud class actions and has a history of significant recoveries in securities litigation [8].